Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | BACE1 | P56817 | 1/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 15/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.53 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | MPEG1 | Q2M385 | 7/20 | 0.42 |
| ▸ | XIAP | P98170 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31203727 | 1.00 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2GLS2 | |
| SCHEMBL28564810 | 1.00 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2GLS2 | |
| SCHEMBL10701374 | 1.00 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2GLS2 | |
| SCHEMBL3264783 | 1.00 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2GLS2 | |
| SCHEMBL10704172 | 1.00 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2GLS2 | |
| SCHEMBL28549544 | 1.00 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2GLS2 | |
| SCHEMBL11018415 | 1.00 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2GLS2 | |
| SCHEMBL10702354 | 1.00 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2GLS2 | |
| SCHEMBL8782213 | 1.00 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2GLS2 | |
| SCHEMBL9181998 | 1.00 | ACHE (1.00) | ACHEBACE1ALOX5PTGS2GLS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307337-A1 | Method Of Treatment Of Obesity | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2024-09-19 | — | — | US | claimed |
| EP-3429625-B1 | METHOD OF TREATMENT OF OBESITY | UNIV LONDON QUEEN MARY (GB) | 2023-04-26 | — | — | EP | claimed |
| US-20210251932-A1 | Method Of Treatment Of Obesity | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2021-08-19 | — | — | US | claimed |
| US-20190105295-A1 | Method Of Treatment Of Obesity | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2019-04-11 | — | — | US | claimed |
| US-12533333-B2 | Method of treatment of obesity | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2026-01-27 | — | — | US | disclosed |
| CN-118903067-A | Methods for treating obesity | 玛丽女王伦敦大学 | 2024-11-08 | — | — | CN | disclosed |
| US-20240307337-A1 | Method Of Treatment Of Obesity | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2024-09-19 | — | — | US | disclosed |
| US-12023313-B2 | Method of treatment of obesity | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2024-07-02 | — | — | US | disclosed |
| EP-3429625-B1 | METHOD OF TREATMENT OF OBESITY | UNIV LONDON QUEEN MARY (GB) | 2023-04-26 | — | — | EP | disclosed |
| US-20210251932-A1 | Method Of Treatment Of Obesity | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2021-08-19 | — | — | US | disclosed |
| US-10925849-B2 | Method of treatment of obesity | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2021-02-23 | — | — | US | disclosed |
| US-20190105295-A1 | Method Of Treatment Of Obesity | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2019-04-11 | — | — | US | disclosed |
| CN-109475635-A | Method for treating obesity | 玛丽女王伦敦大学 | 2019-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533333-B2 | Method of treatment of obesity | GPR119, GPR84, GPR88 | ACHE 1293/4885BACE1 2757/4885ALOX5 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.